A weekly jab at your kitchen table instead of an IV drip at a clinic — that's the change the FDA just approved for Alzheimer's patients on Leqembi.
No more mandatory clinic visits to start treatment.
No more hospital chairs and hour-long infusions.
Just a needle, a caregiver, and a few minutes at home.
Let that sink in for a disease that usually steals independence first.
The drug is Leqembi, made by Eisai and Biogen.
It targets amyloid beta — the sticky protein plaque that builds up in Alzheimer's brains.
Until Monday, starting treatment meant IV infusions at a clinic for 18 months before you could even switch to a simpler maintenance dose.
Now the FDA has cleared Leqembi IQLIK, a subcutaneous shot patients or caregivers can give themselves, right from day one.
Think about who Alzheimer's patients are.
Older. Often frail. Frequently without easy transport.
BMO's Evan Seigerman called it a potential access booster.
Biogen shares jumped 4.5% the same day.
Here's the twist nobody's cheering about.
Citi analysts say don't expect a sudden rush of new patients.
Why?
Because the real bottlenecks were never the needle.
And there's a scientific asterisk too — the subcutaneous version wasn't tested in its own large outcomes trial.
The FDA approved it because it produces equivalent amyloid reduction to the IV version, not because it ran a fresh head-to-head study.
This isn't a cure.
It's convenience — engineered into a disease that rarely offers any.
And sometimes, in medicine, removing friction is its own kind of breakthrough.
That's all for now!
